←
RyvuTx490 posts
RyvuTx avatar

RyvuTx

@RyvuTx

Ryvu Therapeutics is developing novel small molecule therapies that address clinical limitations of current treatments in oncology.

◷ Joined June 2019▧ 473 Photos and videos
RyvuTx avatar
RyvuTx@RyvuTx·Nov 4

MENARINI Group and Ryvu will present the first clinical data from the Phase II JASPIS-01 study of dapolsertib (MEN1703, SEL24) in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. Read more: lnkd.in/d5mf-Y3Z

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Nov 4

The abstracts for the 2026 EORTC-NCI-AACR Symposium (#ENA) are now available online. Ryvu will present two posters featuring preclinical research: RVU602 and ONCO Prime Read more: lnkd.in/dRqJM39i Go to the abstracts: lnkd.in/eJYNE4cB

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Nov 4

Looking ahead to #BIO-Europe in Cologne! In just a few days, Ryvu CEO Pawel Przewiezlikowski and Karolina Osowska, Director of Business Development & Alliance Management, will be there to meet with the biotech and pharma community.

Post attachmentPost attachment
RyvuTx avatar
RyvuTx@RyvuTx·Oct 21

On November 5, Krzysztof Brzozka, Chief Scientific Officer at Ryvu, will speak at the #ADC Payload Summit 2026 in Boston. Join Krzysztof's session and connect with us to discuss the future of ADC payload innovation.

Post attachmentPost attachment
RyvuTx avatar
RyvuTx@RyvuTx·Oct 15

Ryvu presented new preclinical proof-of-concept data for RVU602, our proprietary, potentially first-in-class ADC payload with a mechanism of action distinct from both TOPO1 and tubulin inhibitors. 🔗 Read more: lnkd.in/dU5N4v6P

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Oct 14

Today, Agnieszka Ludwig-Słomczyńska will present new preclinical in vivo proof-of-concept data for RVU602 at World ADC 2026 in San Diego! Join her!

Post attachmentPost attachment
RyvuTx avatar
RyvuTx@RyvuTx·Sep 25

On September 29, Krzysztof Brzozka, CSO at Ryvu, will speak at the Drug Discovery Innovation Programme Europe 2026 in Basel. If you are attending DDIP Europe, join the session and meet Krzysztof in Basel.

Post attachmentPost attachment
RyvuTx avatar
RyvuTx@RyvuTx·Sep 21

Aleksandra Sabiniarz, Director of Research Operations will represent Ryvu at the 25th Scientific Congress of the Polish Pharmaceutical Society in Wrocław, September 22-25. Ola will speak during the first plenary session. Learn more: ptfarmzjazd.pl/

Post attachmentPost attachment
RyvuTx avatar
RyvuTx@RyvuTx·Sep 21

Ryvu has signed a grant agreement with the National Centre for Research and Development. The agreement provides up to PLN 105.6 million in funding for the project “PANACEA-NOVO - patient-oriented innovative targeted therapies for rare cancers” lnkd.in/dr2v5YNj

Post attachmentPost attachment
RyvuTx avatar
RyvuTx@RyvuTx·Sep 17

Ryvu Therapeutics has reported its financial results for H1 2026 and provided an update on recent clinical and corporate progress. Read the H1 2026 report: lnkd.in/eh7jb6QU and the press release: lnkd.in/e4V8zD4H

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Sep 4

On September 9-10, Karolina Osowska will attend the Oncology & Immunology Innovation Partnering & Licensing Summit. If you would like to discuss Ryvu’s oncology pipeline and partnering opportunities, connect with Karolina through the event’s one-to-one partnering portal.

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Aug 18

Today, we are launching Keelira, our dedicated early clinical development services business for biotech and pharma companies seeking to extend oncology programs into Europe. Read the press release: ryvu.com/press-release/ryvu-… Learn more about Keelira: keelira.com

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Aug 14

The MEDWAY project is moving forward, and we are proud to be part of it! The Children’s Memorial Health Institute officially launched a new investigator-initiated, non-commercial Phase I clinical study. More: ryvu.com/press-release/rvu12…

Post attachment
RyvuTx avatar
RyvuTx@RyvuTx·Jul 30

Thank you to Minister Pełczyńska-Nałęcz, Secretary of State Szyszko, and everyone from the Ministry of Development Funds and Regional Policy who joined us for an open and substantive conversation. We look forward to continuing this dialogue!

Po raz pierwszy w historii powstaje lek wynaleziony i w całości opracowany przez naszych naukowców i naszą rodzimą firmę. Tak warto budować rozwój. Wsparte z KPO i Funduszy 🇪🇺🇵🇱

0:28
Katarzyna Pełczyńska avatar
⟳ RyvuTx retweeted
Katarzyna Pełczyńska@Kpelczynska·Jul 30

Po raz pierwszy w historii powstaje lek wynaleziony i w całości opracowany przez naszych naukowców i naszą rodzimą firmę. Tak warto budować rozwój. Wsparte z KPO i Funduszy 🇪🇺🇵🇱

0:28